AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
- Ten presentations at the
International Conference on Alzheimer’s & Parkinson’s Diseases (AD/PDTM) - AC Immune’s Chief Medical Officer to participate in expert forum on immunotherapies in Alzheimer’s disease
Lausanne,
Roundtable discussion
Forum 02: Immunotherapies in AD: from basics to approval
Date: Wed,
Panelist: Forum discussion with Johannes Streffer, M.D., (
Active immunotherapy
ABATE study – Utilizing biomarker-based development for optimized ACI-24, a novel candidate vaccine for the treatment and prevention of Alzheimer’s disease
Date: Sat,
Presenter: Oral presentation by Johannes Streffer, M.D., (
Beneficial effect of ACI-24 vaccination on Abeta plaque pathology and microglial phenotypes in an amyloidosis mouse model
Date: Sat,
Presenter: Oral presentation by
A novel anti-amyloid beta (Abeta) vaccine, a potent immunotherapy for the prevention and treatment of Alzheimer’s disease in Down syndrome
Date: Sat.,
Presenter: On-demand symposium by
VacSYn study design – biomarker-based development for ACI-7104, a novel candidate vaccine for the treatment and prevention of Parkinson’s disease
Date: Available online from Tue,
Presenter: On demand presentation by Dymitr Kostrica, Ph.D. (
Passive immunotherapy
Antibody-mediated inhibition of ASC attenuates inflammasome activation in vitro and in a mouse model of demyelination
Date: Wed,
Presenter: Oral presentation by
Development of TDP-43 immunotherapy blocking transmission of seeding-competent species from ALS/FTD
Date: Thu,
Presenter: Oral presentation by
Small molecules
Discovery of therapeutic small molecules targeting alpha-synuclein aggregation
Date: Fri,
Presenter: On demand presentation by
Diagnostics & biomarkers
Discovery and initial clinical evaluation [18F]ACI-12589, a novel and promising PET-tracer for a-synuclein
Date: Thu,
Presenter: Oral presentation by
Compartmentalization of plasma TDP-43 in platelets: implications for TDP-43-related biomarker development
Date: Thu,
Presenter: Oral presentation by
Optimization of affinity, selectivity and pharmacokinetic profile of TDP-43 PET ligands
Date: Available online from Tue,
Presenter: On demand presentation by Tamara Seredenina, Ph.D. (
About
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| Head of Investor Relations & Corporate Communications Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com |
U.S. Investors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
| International Media Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Attachment
Source: AC Immune SA